LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

Search

AstraZeneca PLC ADR

Fechado

87.48 3.47

Visão Geral

Variação de preço das ações

24h

Atual

Mín

84.55

Máximo

87.51

Indicadores-chave

By Trading Economics

Rendimento

-275M

3.1B

Vendas

869M

14B

P/E

Médio do Setor

30.722

77.256

Rendimento de Dividendos

1.92

Margem de lucro

21.63

Funcionários

94,300

EBITDA

-87M

5B

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+11.73% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

1.92%

2.33%

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

28B

254B

Abertura anterior

84.01

Fecho anterior

87.48

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

AstraZeneca PLC ADR Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de nov. de 2025, 11:47 UTC

Ganhos

AstraZeneca Revenue Climbs on Pipeline Strength -- Update

6 de nov. de 2025, 08:36 UTC

Ganhos

Correction to AstraZeneca Earnings Article

6 de nov. de 2025, 07:40 UTC

Ganhos

AstraZeneca Revenue Climbs on Pipeline Strength, U.S. Price Deal

6 de nov. de 2025, 12:07 UTC

Conversa de Mercado

AstraZeneca Should Continue to Outpace Peers, Stick to Margin Goal -- Market Talk

6 de nov. de 2025, 12:02 UTC

Ganhos

AstraZeneca Sees FY25 Core EPS Increasing by Low Double-Digit Percentage >AZN.LN

6 de nov. de 2025, 12:02 UTC

Ganhos

AstraZeneca Sees FY25 Total Rev Increasing by High Single-Digit Percentage >AZN.LN

6 de nov. de 2025, 12:01 UTC

Ganhos

AstraZeneca 3Q EPS $1.64 >AZN.LN

6 de nov. de 2025, 12:01 UTC

Ganhos

AstraZeneca 3Q Rev $15.2B >AZN.LN

6 de nov. de 2025, 08:45 UTC

Conversa de Mercado
Ganhos

AstraZeneca Growth Leads Pharma Sector, and Next Year Looks Promising Too -- Market Talk

6 de nov. de 2025, 07:03 UTC

Ganhos

AstraZeneca 3Q Pretax Pft $3.24B

6 de nov. de 2025, 07:03 UTC

Ganhos

Analysts Saw AstraZeneca 3Q Net Profit at $2.58B

6 de nov. de 2025, 07:03 UTC

Ganhos

AstraZeneca 3Q Net Pft $2.54B

6 de nov. de 2025, 07:02 UTC

Ganhos

AstraZeneca Backs 2025 View

6 de nov. de 2025, 07:02 UTC

Ganhos

Analysts Saw AstraZeneca 3Q Adjusted EPS at $2.31

6 de nov. de 2025, 07:02 UTC

Ganhos

AstraZeneca 3Q Adj EPS $2.38

6 de nov. de 2025, 07:02 UTC

Ganhos

Analysts Saw AstraZeneca 3Q Revenue at $14.78B

6 de nov. de 2025, 07:01 UTC

Ganhos

AstraZeneca 3Q Rev $15.19B

6 de nov. de 2025, 07:00 UTC

Ganhos

AstraZeneca PLC 3Q Adj EPS $2.38

6 de nov. de 2025, 07:00 UTC

Ganhos

AstraZeneca PLC 3Q Pretax Pft $3.24B

6 de nov. de 2025, 07:00 UTC

Ganhos

AstraZeneca PLC 3Q EPS $1.62

6 de nov. de 2025, 07:00 UTC

Ganhos

AstraZeneca PLC 3Q Rev $15.19B

6 de nov. de 2025, 07:00 UTC

Ganhos

AstraZeneca PLC 3Q Oper Pft $3.58B

6 de nov. de 2025, 07:00 UTC

Ganhos

AstraZeneca PLC 3Q Net Pft $2.53B

5 de nov. de 2025, 10:38 UTC

Ganhos

AstraZeneca's U.S. Drug-Pricing Deal, Pipeline in Focus -- Earnings Preview

30 de out. de 2025, 13:22 UTC

Ganhos

Eli Lilly Stock Rises on Earnings as Investors Await Trump Drug Pricing Deal -- Barrons.com

30 de out. de 2025, 11:13 UTC

Ganhos

Eli Lilly Stock Rises on Earnings as Investors Await Trump Drug Pricing Deal -- Barrons.com

30 de out. de 2025, 10:58 UTC

Ganhos

Eli Lilly Stock Rises on Earnings as Investors Await Trump Drug Pricing Deal -- Barrons.com

16 de out. de 2025, 09:31 UTC

Conversa de Mercado
Ganhos

AstraZeneca's Pipeline Weakness, Patent Expirations Dim Outlook -- Market Talk

13 de out. de 2025, 09:33 UTC

Ações em Alta

Stocks to Watch Monday: MP Materials, AMD, Nvidia, Alibaba -- WSJ

13 de out. de 2025, 08:06 UTC

Conversa de Mercado

AstraZeneca Should Face Limited Impact From Trump Pricing Deal -- Market Talk

Comparação entre Pares

Variação de preço

AstraZeneca PLC ADR Previsão

Preço-alvo

By TipRanks

11.73% parte superior

Previsão para 12 meses

Média 94.5 USD  11.73%

Máximo 101 USD

Mínimo 85 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para AstraZeneca PLC ADR - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

5

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

N/A / 69.55Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre AstraZeneca PLC ADR

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
help-icon Live chat